Lipocine Announces Results From Pre-NDA Meeting for LPCN 1021, an Oral Testosterone Product Candidate
March 24, 2015 at 09:01 AM EDT
Lipocine Inc. (Nasdaq: LPCN), a specialty pharmaceutical company, today announced that it has completed its pre-New Drug Application ...
